Employees: 295
Size Jin Medical International (ZJYL) is a United States Health Care company (Medical Specialties) with a market value of $532M, the 2632nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.36 on 18 Nov 2026.
Performance Over six months the shares gained 47.4%, against -23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue fell 13.6% over the last twelve months (peer median +6.1%); the operating margin is 2.1% (peer median 2.5%).
Valuation It trades at 26.5× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 19).
Capital Return on invested capital runs 17.9 points below its cost of capital (19.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $19.7M | $20.7M | $23.5M | $19.8M | $19.2M |
| Revenue growth | — | -12% | +19% | +3% | — |
| Gross profit | $6.04M | $6.04M | $9.50M | $6.78M | $6.20M |
| EBITDA | $704,460 | $932,860 | $3.97M | $3.09M | $2.49M |
| Net income | $1.17M | $1.19M | $3.68M | $2.88M | $2.71M |
| Free cash flow | -$6.96M | -$3.73M | -$1.35M | $2.99M | $1.54M |
| Capital expenditure | $6.37M | $6.63M | $1.12M | $113,937 | $40,166 |
| Total debt | n/a | $18.5M | $11.4M | $4.11M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZJYL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +65.5% | -6.7% | highest of 21 |
| 6-month return | +47.4% | -23.4% | 3rd highest of 21 |
| Distance from 52-week high | -40.8% | -44.6% | 9th highest of 21 |
| Revenue growth (TTM) | -13.6% | +6.1% | 2nd lowest of 21 |
| Operating margin | 2.1% | 2.5% | 10th lowest of 21 |
| EV / Sales | 26.5× | 3.0× | 2nd most expensive of 19 |
| ROIC minus cost of capital | -17.9 pp | -2.2 pp | 3rd lowest of 18 |
| Net debt / EBITDA | -13.5× | -1.7× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | 26.5× | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | 0.8× | n/a | n/a |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | 6.7× | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | 1.5× | 6.0% | -7.7% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | 5.5× | 15.0% | -19.8% |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 3.9× | 0.4% | -13.2% |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 1.6× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | 125.0× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | 5.4× | 30.8% | -18.6% |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | 5.9× | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 1.6× | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | 1.6× | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 5.3× | 20.1% | +4.2% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 1.4× | 4.5% | +5.0% |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | 6.7× | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 3.3× | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 2.2× | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 1.3× | -6.5% | -4.3% |